Apyx Medical Inc

Apyx Medical Corp delivered a strong first quarter for fiscal 2026, beating Wall Street expectations on both the top and bottom lines and extending its streak of consensus EPS beats to four consecutive quarters. The medical device maker posted revenue of $12.49 million, up 32.5% year over year and well ahead of the $10.77 million analyst estimate, while its per-share loss of $0.05 came in notably better than the $0.11 consensus forecast, a 54.55% positive surprise. The primary driver was the Surgical Aesthetics segment, which generated $10.73 million in revenue, fueled by domestic commercial momentum from the AYON Body Contouring System and a 62.9% surge in international revenue to $4.38 million, with South Korea emerging as a particularly promising new market following December 2025 regulatory approval. Gross margin expanded to 63.5% from 60.1% a year ago, reflecting a favorable mix shift toward higher-margin aesthetics products. Encouraged by the quarter's performance, management raised its full-year 2026 revenue guidance to $59.00 million to $60.00 million, up from the prior range of $57.50 million to $58.50 million.